Acute Coronary Syndrome
Conditions
Keywords
Wnt signaling
Brief summary
This study aims to find the change of serum wnt effectory moleculars and the association with Hs-CRP，cTnI and Prognosis in Patients with Acute Coronary Syndrome.
Detailed description
It has been reported that wnt effecory moleculars (wnt2, wnt4, wnt11,wnt10b, DKK1, DKK2) increased in myocardium at acute phase after myocardium infarction in animal experiment. These moleculars can be detected in serum or plasma from human subjects. However, there is few relevant studies about wnt2 and wnt4 concentration in patients with acute coronary syndrome. This study valuates the serum wnt2 and wnt4 concentration in patients with acute coronary syndrome. It will possibly enable to find the relationship between serum wnt2 or wnt4 concentration and Hs-CRP, cTnI and prognosis in patients with Acute Coronary Syndrome.
Interventions
OTHERCirculating wnt 2 and wnt 4 concentration
Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission. Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
Sponsors
Fudan University
The First Affiliated Hospital of Dalian Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Inclusion criteria
.diagnosed as acute coronary syndrome, including STEMI and NST-ACS. * with left ventricular ejection fraction（LVEF）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked
Exclusion criteria
* • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum wnt2 and wnt4 concentration | 12 months | Serum wnt2 and wnt4 concentration in ng/ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relationship between wnt2 or wnt4 and high sensitive C reaction protein (hs-CRP) concentration | 12 months | Correlation of wnt2 and wnt4 with hs-CRP concentration |
| Relationship between wnt2 or wnt4 and Troponin-I (Tn-I) concentration | 12 months | Correlation of wnt2 and wnt4 with Tn-I concentration |
| MACEs during 12-month follow-up | 12 months | Association of wnt2 or wnt4 concentration with prognosis |
Countries
China
Outcome results
None listed